Anywhere under £45.27, GSK’s share price looks cheap to me

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I’ve investigated whether this is the case.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GSK’s (LSE: GSK) share price has traded in an unusually wide range for it over the past year. It recorded a 12-month high of £18.19 on 15 May. And since then hit a one-year low of £13.05 on 18 November. Currently, it is much nearer that low than the high, at just £13.58.

This scale of the loss – 25% at present – flags the possibility to me of a bargain buying opportunity. New shares at such a low price could add value to my existing holding in GSK.

But I need to check that there is value in the stock. Such a fall could also indicate that the company is simply worth less than it was before or that the market is catching up to the true value of the shares.

Should you invest £1,000 in Gsk right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Gsk made the list?

See the 6 stocks

Are the shares undervalued right now or not?

The first part of my pricing assessment compares GSK’s key valuations with those of its competitors.

On the price-to-earnings ratio, it trades at just 21.6 – bottom of its peer group, which averages 29.1. This comprises Merck KGaA at 22.8, both Zoetis and AstraZeneca at 31, and CSL at 31.4. So, GSK looks very undervalued on that basis.

The same is true on the key price-to-book and price-to-sales ratios. On the former, GSK currently trades at 3.9 against a competitor average of 6.6. And on the latter, it is presently at 1.7 compared to a 5.2 average for its peers.

The second part of my pricing assessment examines where GSK shares should be, based on future cash flow forecasts. This discounted cash flow analysis  shows the stock is 70% undervalued at its current £13.58 price.

Therefore, the fair value of the stock is technically £45.27. Market unpredictability may move it lower or higher than this. But it underlines to me that the stock is absolutely packed with value right now.

Created with Highcharts 11.4.3GSK PriceZoom1M3M6MYTD1Y5Y10YALL22 Jan 202022 Jan 2025Zoom ▾Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '2520212021202220222023202320242024www.fool.co.uk

How does the core business look?

A steady trickle of bad news has weighed on GSK’s share price over the past 12 months.

Ongoing litigation over its Zantac drug’s link to cancer is one. And this remains a primary risk for the firm, in my view.

The 23 December US Food and Drug Administration’s de-authorisation of for four Covid antibody-based drugs for emergency use is another. This includes GSK’s Sotrovimab.

That said, there have been several positive developments as well. The major one in my view is the $1.15bn acquisition of US biotech firm IDRx announced on 13 January.

It is part of the firm’s strategic shift towards gastrointestinal cancers to compensate for a declining vaccines business.

Factoring in all positive and negative factors to date, analysts forecast GSK’s earnings will increase 20.7% each year to end-2027. And it is this growth that ultimately drives a firm’s share price (and dividend) higher.

Will I buy more shares?

Currently, the yield on GSK shares is 4.3%. But analysts’ forecast it will rise in 2025 to 4.8% and in 2026 to 5.2%. These return rates compare favourably to the FTSE 100 average of 3.6%.

And the stellar earnings growth projections should also drive the share price much higher, in my view.

As such, I will be buying more GSK stock very soon.

Should you invest £1,000 in Gsk right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Gsk made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Simon Watkins has positions in AstraZeneca Plc and GSK. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Just released: our 3 top small-cap stocks to consider buying in April [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

Here’s why Tesla stock just rocketed 22.7%! Is it time to buy?

This writer wonders whether the news that sent Tesla stock soaring yesterday is a true gamechanger for the electric vehicle…

Read more »

Investing Articles

2 quality UK stocks to consider buying as share prices rally

With UK stocks moving higher, it might look as though investors with cash on hand have missed their chance. But…

Read more »

Investing Articles

How much £10,000 invested in Lloyds shares is forecast to be worth in 12 months

Harvey Jones is looking past today's stock market volatility to see where Lloyds shares may stand in a year's time.…

Read more »

Investing Articles

How Warren Buffett stays ahead of the stock market

When share prices fall, everyone suddenly wants to be like Warren Buffett. But what’s the secret to the Berkshire Hathaway…

Read more »

Investing Articles

Cheap UK dividend shares to consider buying right now

We're only just past the first quarter of 2025, but it already looks like the year could be another good…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

What the heck is going on with the Barclays share price now?

The Barclays share price surged 25% as the market open on 10 April. Once again, the volatility’s been driven by…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

What the devil’s going on with the HSBC share price?

The HSBC share price has actually been less volatile than some of its peers, despite its Chinese operations suggesting it’s…

Read more »